Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Ping An-Shionogi

    • Home
    • Ping An-Shionogi
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing Secures Exclusive Promotion Rights for Naldemedine in China

Fineline Cube Jan 2, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced an exclusive market promotion agreement between its...

Drug

Shionogi Files NDA for S-217622 COVID-19 Antiviral Drug in China

Fineline Cube Jul 5, 2022

Japan-based Shionogi & Co., Ltd has submitted a New Drug Application (NDA) to the National...

Recent updates

  • Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia
  • Apeloa Partners with MindRank on AI Drug Development Platform
  • China Drug Administration Implementation Regulations Set for May 2026 Launch
  • Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials
  • Hengrui’s HRS-5346 Lp(a) Inhibitor Gets China Breakthrough Therapy Designation in $1.97B Merck Deal
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Leqvio Gets NMPA Nod for Monotherapy in China Hypercholesterolemia

Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Policy / Regulatory

China Drug Administration Implementation Regulations Set for May 2026 Launch

Company Drug

Henlius Triple Combo Gets NMPA Nod for Advanced Solid Tumor Trials

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.